MolecuLight enters distribution agreement with Smith & Nephew
Medical imaging company MolecuLight (Toronto, ON, Canada) has entered into an exclusive global distribution agreement with medical technology investor Smith & Nephew (Kingston upon Hull, England) to distribute its MolecuLight i:X imaging device. The device offers real-time fluorescence image-guidance solutions that provide new information about wound bacterial burden and wound size, with the goal of assisting clinicians in making improved diagnostic and treatment decisions.
Related: Fluorescence microscopy method sheds light on poor wound healing in diabetics
The MolecuLight i:X device enables healthcare professionals to see the actual accumulation of fluorescent bacteria in a wound, even when not visible to the naked eye, explains Andy Weymann, MD, chief medical officer at Smith & Nephew. It also offers guiding debridement, wound cleansing, and wound measurement, he says.
The device is currently CE-Marked and approved by Health Canada, and is available in the European Union and Canada. It is pending De Novo approval in the U.S.
For more information, please visit www.moleculight.com.